NGI+ – The Next Generation of APSD Testing
Enhanced Durability.
Greater Compatibility.
Reliable APSD Data.
For experts conducting Aerodynamic Particle Size Distribution (APSD) measurements, the NGI+ takes inhalation drug testing to the next level. Built upon the trusted Next Generation Impactor (NGI) design, the NGI+ features enhanced corrosion resistance, improved chemical compatibility, and extended equipment life - ensuring more reliable, repeatable APSD results across a wider range of formulations.
NGI+ Advantages for APSD Testing
- Precise APSD Characterization – Maintains industry-leading impactor performance while supporting a broader range of drugs and delivery systems.
- Enhanced Corrosion & Chemical Resistance – Ideal for nebulizers, biologics, and high-saline formulations, ensuring long-term impactor integrity.
- More Robust Cleaning Options – Supports harsher cleaning agents and automated cleaning processes, reducing variability and cross-contamination risks.
- Seamless Integration & Upgrades – Available as a direct upgrade for existing NGI systems, extending instrument lifespan without disrupting workflows.
Expanding Your APSD Testing Capabilities
- Nebulizer & Biologic Testing – Overcomes the challenges of high-saline and protein-based formulations, ensuring impactor reliability.
- Increased Method Robustness – Reduces material degradation, providing consistent APSD data over time.
- Faster, More Reliable Cleaning – Enables automated or chemical-based cleaning, improving efficiency and reproducibility.